LOGIN  |  REGISTER
Assertio
Cue Biopharma

Option Care Health to Participate in Upcoming Investor Conferences

May 18, 2023 | Last Trade: US$31.60 0.27 -0.85

BANNOCKBURN, Ill., May 18, 2023 (GLOBE NEWSWIRE) -- Option Care Health Inc. (“Option Care Health”) (NASDAQ: OPCH), the nation’s largest independent national provider of home and alternate site infusion services, will participate in the following upcoming investor conferences:

  • William Blair’s 43rd Annual Growth Stock Conference, being held in Chicago, on Tuesday, June 6, 2023, including a fireside chat at 11:30am CT.
  • The Jefferies Healthcare Conference, being held in New York City, on Wednesday, June 7, 2023, including a fireside chat at 12:30pm ET.
  • The 44th Annual Goldman Sachs Healthcare Conference, being held in Dana Point, CA, on Monday, June 12, 2023, including a fireside chat at 3:20pm PT.

Webcast links and related presentation materials will be available online at https://investors.optioncarehealth.com.

About Option Care Health

Option Care Health is the nation’s largest independent provider of home and alternate site infusion services. With over 7,500 team members including more than 4,500 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states. Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and team members. To learn more, please visit our website at OptionCareHealth.com.

For Investor Inquiries:

Mike Shapiro, Chief Financial Officer
Option Care Health
312.940.2538
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page